Previous 10 | Next 10 |
Clinical-stage biotech Allarity Therapeutics ( NASDAQ: ALLR ) announced on Tuesday that its board decided to reprioritize the company’s pipeline strategy towards the advancement of combination therapies and move away from the development of monotherapies. Allarity (...
New strategy align s with ongoing shift in oncology standard - of - care towards combination therapies Combination therapy focus expected to improve the C ompany’s future funding a nd commercial pro...
Gainers: Leafly Holdings ( LFLY ) +92% . Blue Water Vaccines ( BWV ) +57% . Pzena Investment Management ( PZN ) +46% . Pagaya Technologies ( PGY ) +26% . Green Giant ( GGE ) +26% . Allarity ( ALLR ) +24% . Teva Ph...
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press Release Cambridge, MA , U.S.A . ( Ju ly 11 , 2022 ) — Allarity Therapeutics, Inc. (“Allarity” ...
Gainers: Alpha Tau Medical ( DRTS ) +42% . Precigen ( PGEN ) +20% . Amylyx Pharmaceuticals ( AMLX ) +18% . bluebird bio ( BLUE ) +13% . Talaris Therapeutics ( TALS ) +11% . Losers: Revelation Biosciences ( REVB ...
The board of clinical-stage pharmaceutical company Allarity Therapeutics ( NASDAQ: ALLR ) appointed Chief Business Officer James Cullem interim CEO and Director of Financial Reporting Joan Brown interim CFO, with immediate effect. Former CEO Steve Carc...
Cambridge, MA U.S.A . ( June 15 , 202 2 ) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ...
Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...
Allarity Therapeutics press release (NASDAQ:ALLR): Q1 GAAP EPS of -$0.56. As of March 31, 2022, Allarity’s cash was $14.5 million, as compared to $19.6 million as of December 31, 2021. For further details see: Allarity Therapeutics GAAP EPS of -$0.56
Cambridge, MA U.S.A. ( May 27 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagn...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...